{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-23-000067","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2023-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.302221+00:00","generated_at":"2026-06-13T20:08:24.944034+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Allogene reports updated Phase 1 data for ALLO-501/501A in r/r LBCL with 58% ORR and 42% CR","bullets":["In 33 CAR T-naïve patients, ORR 58%, CR 42%; 30% maintained CR at 6 months across all patients.","Phase 2 regimen (12 patients): ORR 67%, CR 58%; median duration of response 23.1 months.","No Grade ≥3 CRS, no ICANS or GvHD; cytopenia and infections manageable, comparable to autologous CAR T.","Company expects to complete enrollment of potentially pivotal Phase 2 ALPHA2 trial in 1H2024; plans to open sites in Europe, Canada, Australia in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-23-000067","json":"https://secwatch.observer/filing/0001737287-23-000067.json","markdown":"https://secwatch.observer/filing/0001737287-23-000067.md","text":"https://secwatch.observer/filing/0001737287-23-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000067/0001737287-23-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000067/allo-20230615.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T20:08:24.944034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}